(RTTNews) - Antengene Corporation Limited (6996.HK) announced that China National Medical Products Administration or NMPA has approved the investigational new drug application for the Phase Ib/II CLINCH-2 study evaluating ATG-022 in combination with Merck & Co., Inc.'s anti-PD-1 therapy, KEYTRUDA, as well as ATG-022 in combination with pembrolizumab and chemotherapy.
Antengene Limited is a commercial-stage biotech company focused on developing first-in-class/best-in-class therapeutics for diseases with significant unmet medical needs. To date, Antengene has obtained 32 IND approvals in the U.S. and Asia, and submitted NDAs in 11 Asia Pacific markets.
For More Such Health News, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
